Dutch consumer electronics giant Philips Electronics NV (PHGFF.PK, PHG) reported Monday that its fourth-quarter income from operations was 24 million euros, including charges of 363 million euros connected with the Respironics consent decree, which has been agreed with the US Department of Justice or DOJ, representing the US Food and Drug Administration.
Shares of Philips Electronics NV were losing more than 6 percent in the morning trading in Amsterdam as well as in pre-market activity on the NYSE after the Dutch consumer electronics giant reported Monday a drop in fourth-quarter income from operations amid weak sales.